1. Home
  2. HALO vs RGEN Comparison

HALO vs RGEN Comparison

Compare HALO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • RGEN
  • Stock Information
  • Founded
  • HALO 1998
  • RGEN 1981
  • Country
  • HALO United States
  • RGEN United States
  • Employees
  • HALO N/A
  • RGEN N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • RGEN Medical/Dental Instruments
  • Sector
  • HALO Health Care
  • RGEN Health Care
  • Exchange
  • HALO Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • HALO 7.4B
  • RGEN 8.0B
  • IPO Year
  • HALO N/A
  • RGEN N/A
  • Fundamental
  • Price
  • HALO $49.20
  • RGEN $124.32
  • Analyst Decision
  • HALO Buy
  • RGEN Buy
  • Analyst Count
  • HALO 9
  • RGEN 12
  • Target Price
  • HALO $63.56
  • RGEN $172.67
  • AVG Volume (30 Days)
  • HALO 3.0M
  • RGEN 830.2K
  • Earning Date
  • HALO 05-06-2025
  • RGEN 04-29-2025
  • Dividend Yield
  • HALO N/A
  • RGEN N/A
  • EPS Growth
  • HALO 55.40
  • RGEN N/A
  • EPS
  • HALO 3.76
  • RGEN N/A
  • Revenue
  • HALO $1,084,306,000.00
  • RGEN $650,429,000.00
  • Revenue This Year
  • HALO $24.79
  • RGEN $13.93
  • Revenue Next Year
  • HALO $22.65
  • RGEN $14.35
  • P/E Ratio
  • HALO $13.36
  • RGEN N/A
  • Revenue Growth
  • HALO 25.64
  • RGEN 4.88
  • 52 Week Low
  • HALO $41.28
  • RGEN $102.97
  • 52 Week High
  • HALO $70.51
  • RGEN $182.52
  • Technical
  • Relative Strength Index (RSI)
  • HALO 33.34
  • RGEN 42.03
  • Support Level
  • HALO $47.50
  • RGEN $123.10
  • Resistance Level
  • HALO $69.94
  • RGEN $135.47
  • Average True Range (ATR)
  • HALO 3.28
  • RGEN 7.05
  • MACD
  • HALO -1.54
  • RGEN -0.99
  • Stochastic Oscillator
  • HALO 4.13
  • RGEN 6.24

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: